ELEX BIOTECH, LLC

Biotech · Private

Novel small-molecule compounds targeting RyR2 calcium release channel for catecholaminergic polymorphic ventricular tachycardia (CPVT) treatment

Grants
$4.9M
6 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT$750,385
Federal grantDepartment of Health and Human Services · Phase I · Development of novel compounds for the treatment of atrial fibrillation$427,638
Federal grantDepartment of Health and Human Services · Phase II · Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT$749,998
Federal grantDepartment of Health and Human Services · Phase II · Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT$999,103
Federal grantDepartment of Health and Human Services · Phase II · Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT$966,380
Federal grantDepartment of Health and Human Services · Phase II · Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT$971,323
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1136REGENOSINE INC——
1137Synata Bio, Inc.—$52M
1138SYNSORYBIO, INC.——
1139ELEX BIOTECH, LLC——
1140NITRO BIOSCIENCES INC.——
1141PROTON BIO, INC.——
1142REZIGENE, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • Compounds For Treatment Of Cardiac Arrhythmiasapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.